IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma (Q43040465)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 May 2011

Language	Label	Description	Also known as
English	IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma	scientific article published on 23 May 2011

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

14

object named as

H Ohdan

1 reference

Europe PubMed Central

12 November 2017

author name string

T Kawaoka

1

1 reference

Europe PubMed Central

12 November 2017

H Aikata

2

1 reference

Europe PubMed Central

12 November 2017

S Takaki

3

1 reference

Europe PubMed Central

12 November 2017

A Hiramatsu

4

1 reference

Europe PubMed Central

12 November 2017

K Waki

5

1 reference

Europe PubMed Central

12 November 2017

N Hiraga

6

1 reference

Europe PubMed Central

12 November 2017

D Miki

7

1 reference

Europe PubMed Central

12 November 2017

M Tsuge

8

1 reference

Europe PubMed Central

12 November 2017

M Imamura

9

1 reference

Europe PubMed Central

12 November 2017

Y Kawakami

10

1 reference

Europe PubMed Central

12 November 2017

S Takahashi

11

1 reference

Europe PubMed Central

12 November 2017

H Ochi

12

1 reference

Europe PubMed Central

12 November 2017

H Tashiro

13

1 reference

Europe PubMed Central

12 November 2017

K Chayama

15

1 reference

Europe PubMed Central

12 November 2017

publication date

23 May 2011

1 reference

Europe PubMed Central

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

12 November 2017

18

1 reference

Europe PubMed Central

12 November 2017

10

1 reference

Europe PubMed Central

12 November 2017

e550-60

1 reference

Europe PubMed Central

12 November 2017

Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

A high-throughput SNP typing system for genome-wide association studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01468.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2011.01468.X

1 reference

Europe PubMed Central

12 November 2017

release_7mrohecyz5byjaiyjaccyvcu5i

1 reference

https://api.fatcat.wiki/v0/release/7mrohecyz5byjaiyjaccyvcu5i

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43040465&oldid=1978317026"